Auna S.A. Earnings Call Transcripts
Fiscal Year 2026
-
Q1 2026 saw 10% FX-neutral revenue growth and strong cash flow, despite a 5% drop in adjusted EBITDA due to extraordinary items. Segment momentum was led by Mexico and Colombia, with Peru impacted by revenue adjustments. Guidance for 2026 is reaffirmed, with margin and cash flow improvements expected in H2.
Fiscal Year 2025
-
Stabilized Mexico operations and strong Peru performance offset earlier setbacks, with consolidated revenue up 6% and adjusted net income more than tripling year-over-year. Guidance for 2026 targets 12% growth in both revenue and EBITDA, supported by new contracts, cost controls, and a strengthened capital structure.
-
Flat consolidated results as Peru and Colombia delivered strong growth, offsetting Mexico's 12% revenue decline due to operational challenges. Debt refinancing improved the capital structure, and a new partnership with Sojitz supports a $500M investment plan in Mexico, with growth expected to resume in 2026.
-
Consolidated FX-neutral EBITDA grew 5% year-over-year, with Mexico, Peru, and Colombia all contributing. Adjusted net income surged, margins held steady, and risk-sharing models expanded in Colombia. Near-term growth faces uncertainty from Mexico's trade issues and Colombia's payer risks.
-
First quarter results were mixed, with Peru delivering strong growth and Mexico facing operational setbacks that led to lower volumes and revenue. Colombia saw improved cash flow from risk-sharing models, while the company maintained a solid financial position and remains focused on recovery and expansion.
Fiscal Year 2024
-
Achieved strong 2024 results with 20% adjusted EBITDA growth, led by Peru and Mexico, while Colombia faced payer-related challenges. Deleveraging continued, with net debt/EBITDA at 3.6x and robust free cash flow. 2025 outlook is positive but cautious due to Colombia's uncertainties.
-
Adjusted EBITDA rose 23% year-over-year, with strong growth in Mexico and Peru and cautious expansion in Colombia. Net debt to Adjusted EBITDA improved to 3.7x, and guidance for 20% FX neutral EBITDA growth is reaffirmed. OncoMexico's pilot phase is progressing well, with robust B2B interest.
-
Q2 2024 saw accelerated growth, with revenue up 13% and adjusted EBITDA up 25% year-over-year (FX neutral), driven by strong results in Peru and Colombia and improving performance in Mexico. OncoMexico launched, and deleveraging continued, with net debt/EBITDA at 4.13x.